• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Epidemiology . OpenSAFELY: Effectiveness of COVID-19 vaccination in children and adolescents

tetano

Editor, Senior Moderator
Epidemiology


. 2025 Sep 23.
doi: 10.1097/EDE.0000000000001908. Online ahead of print. OpenSAFELY: Effectiveness of COVID-19 vaccination in children and adolescents

Colm D Andrews[SUP] 1 [/SUP], Edward P K Parker[SUP] 2 [/SUP], Elsie Horne[SUP] 3 [/SUP], Venexia Walker[SUP] 3 [/SUP], Tom Palmer[SUP] 3 [/SUP], Andrea L Schaffer[SUP] 1 [/SUP], Amelia Ca Green[SUP] 1 [/SUP], Helen J Curtis[SUP] 1 [/SUP], Alex J Walker[SUP] 1 [/SUP], Lucy Bridges[SUP] 1 [/SUP], Christopher Wood[SUP] 1 [/SUP], Victoria Speed[SUP] 1 [/SUP], Christopher Bates[SUP] 4 [/SUP], Jonathan Cockburn[SUP] 4 [/SUP], John Parry[SUP] 4 [/SUP], Amir Mehrkar[SUP] 1 [/SUP], Brian MacKenna[SUP] 1 [/SUP], Sebastian Cj Bacon[SUP] 1 [/SUP], Ben Goldacre[SUP] 1 [/SUP], Miguel A Hernan[SUP] 5 [/SUP], Jonathan Ac Sterne[SUP] 3 [/SUP], William J Hulme[SUP] 1 [/SUP]; OpenSAFELY Collaborative



Affiliations
Abstract

Background: We assessed the safety and effectiveness of first and second dose BNT162b2 COVID-19 vaccination, offered as part of the national COVID-19 vaccine roll-out from September 2021, in children and adolescents in England.
Methods: Our observational study using OpenSAFELY-TPP, included adolescents aged 12-15 years, and children aged 5-11 years. It compared individuals receiving i) first vaccination to unvaccinated controls and ii) second vaccination to single-vaccinated controls. We matched vaccinated individuals with controls on age, sex, and other important characteristics. Outcomes were positive SARS-CoV-2 test (adolescents only); COVID-19 accident and emergency (A&E) attendance; COVID-19 hospitalization; COVID-19 critical care admission; COVID-19 death, with safety outcomes A&E attendance, unplanned hospitalization, pericarditis, and myocarditis.
Results: Amongst 820,926 previously unvaccinated adolescents, 20-week incidence rate ratios (IRR) comparing vaccination with no vaccination were 0.74 for positive SARS-CoV-2 test, 0.60 for COVID-19 A&E attendance and 0.58 for COVID-19 hospitalization. Amongst 441,858 adolescents who had received first vaccination IRRs comparing second dose with single-vaccination were 0.67 for positive SARS-CoV-2 test, 1.00 for COVID-19 A&E attendance and 0.60 for COVID-19 hospitalisation. In both children groups COVID-19-related outcomes were too rare to allow IRRs to be estimated precisely. Across all analyses there were no COVID-19-related deaths, and fewer than seven COVID-19-related critical care admissions. Myocarditis and pericarditis were documented only in the vaccinated groups, with rates of 27 and 10 cases/million after first and second doses respectively.
Conclusions: BNT162b2 vaccination in adolescents reduced COVID-19 A&E attendance and hospitalisation, although these outcomes were rare. Protection against positive SARS-CoV-2 tests was transient.

Keywords: COVID; Coronavirus; Epidemiology; Pandemics; Pediatrics; Vaccines.

 
Back
Top Bottom